Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer
The clinical parameters and the histological and immunohistochemical findings of a prospective protocolized series of 27 prostate carcinoma patients with oligometastatic disease followed homogeneously were analyzed. Lymph nodes (81.5%) and bones (18.5%) were the only metastatic sites. Local control...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/10/4/265 |
| _version_ | 1797545745189961728 |
|---|---|
| author | Claudia Manini Alba González David Büchser Jorge García-Olaverri Arantza Urresola Ana Ezquerro Iratxe Fernández Roberto Llarena Iñaki Zabalza Rafael Pulido Arkaitz Carracedo Alfonso Gómez-Iturriaga José I. López |
| author_facet | Claudia Manini Alba González David Büchser Jorge García-Olaverri Arantza Urresola Ana Ezquerro Iratxe Fernández Roberto Llarena Iñaki Zabalza Rafael Pulido Arkaitz Carracedo Alfonso Gómez-Iturriaga José I. López |
| author_sort | Claudia Manini |
| collection | DOAJ |
| description | The clinical parameters and the histological and immunohistochemical findings of a prospective protocolized series of 27 prostate carcinoma patients with oligometastatic disease followed homogeneously were analyzed. Lymph nodes (81.5%) and bones (18.5%) were the only metastatic sites. Local control after metastatic directed treatment was achieved in 22 (81.5%) patients. A total of 8 (29.6%) patients developed castration-resistant prostate cancer. Seventeen (63%) patients presented with non-organ confined disease. The Gleason index 8–10 was the most frequently observed (12 cases, 44.4%) combined grade. Positive immunostainings were detected with androgen receptor (100%), PGP 9.5 (74%), ERG (40.7%), chromogranin A (29.6%), and synaptophysin (18.5%) antibodies. The Ki-67 index value > 5% was observed in 15% of the cases. L1CAM immunostaining was negative in all cases. Fisher exact test showed that successful local control of metastases was associated to mild inflammation, organ confined disease, Ki-67 index < 5%, and Gleason index 3 + 3. A castration resistant status was associated with severe inflammation, atrophy, a Gleason index higher than 3 + 3, Ki-67 index ≥ 5%, and positive PGP 9.5, chromogranin A, and synaptophysin immunostainings. In conclusion, oligometastatic prostate adenocarcinoma does not have a specific clinical-pathologic profile. However, some histologic and immunohistochemical parameters of routine use may help with making therapeutic decisions. |
| first_indexed | 2024-03-10T14:20:21Z |
| format | Article |
| id | doaj.art-4b1338e8b18948038059c65094d4e046 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T14:20:21Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-4b1338e8b18948038059c65094d4e0462023-11-20T23:26:58ZengMDPI AGJournal of Personalized Medicine2075-44262020-12-0110426510.3390/jpm10040265Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate CancerClaudia Manini0Alba González1David Büchser2Jorge García-Olaverri3Arantza Urresola4Ana Ezquerro5Iratxe Fernández6Roberto Llarena7Iñaki Zabalza8Rafael Pulido9Arkaitz Carracedo10Alfonso Gómez-Iturriaga11José I. López12Department of Pathology, San Giovanni Bosco Hospital, 10154 Turin, ItalyDepartment of Radiation Oncology, Cruces University Hospital, 48903 Barakaldo, SpainDepartment of Radiation Oncology, Cruces University Hospital, 48903 Barakaldo, SpainDepartment of Urology, Cruces University Hospital, 48903 Barakaldo, SpainDepartment of Radiodiagnostics, Cruces University Hospital, 48903 Barakaldo, SpainDepartment of Radiodiagnostics, Cruces University Hospital, 48903 Barakaldo, SpainDepartment of Nuclear Medicine, Cruces University Hospital, 48903 Barakaldo, SpainDepartment of Urology, Cruces University Hospital, 48903 Barakaldo, SpainDepartment of Pathology, Galdakao Hospital, 48960 Galdakao, SpainBiocruces-Bizkaia Health Research Institute, 48903 Barakaldo, SpainIkerbasque, The Basque Foundation for Science, 48009 Bilbao, SpainDepartment of Radiation Oncology, Cruces University Hospital, 48903 Barakaldo, SpainBiocruces-Bizkaia Health Research Institute, 48903 Barakaldo, SpainThe clinical parameters and the histological and immunohistochemical findings of a prospective protocolized series of 27 prostate carcinoma patients with oligometastatic disease followed homogeneously were analyzed. Lymph nodes (81.5%) and bones (18.5%) were the only metastatic sites. Local control after metastatic directed treatment was achieved in 22 (81.5%) patients. A total of 8 (29.6%) patients developed castration-resistant prostate cancer. Seventeen (63%) patients presented with non-organ confined disease. The Gleason index 8–10 was the most frequently observed (12 cases, 44.4%) combined grade. Positive immunostainings were detected with androgen receptor (100%), PGP 9.5 (74%), ERG (40.7%), chromogranin A (29.6%), and synaptophysin (18.5%) antibodies. The Ki-67 index value > 5% was observed in 15% of the cases. L1CAM immunostaining was negative in all cases. Fisher exact test showed that successful local control of metastases was associated to mild inflammation, organ confined disease, Ki-67 index < 5%, and Gleason index 3 + 3. A castration resistant status was associated with severe inflammation, atrophy, a Gleason index higher than 3 + 3, Ki-67 index ≥ 5%, and positive PGP 9.5, chromogranin A, and synaptophysin immunostainings. In conclusion, oligometastatic prostate adenocarcinoma does not have a specific clinical-pathologic profile. However, some histologic and immunohistochemical parameters of routine use may help with making therapeutic decisions.https://www.mdpi.com/2075-4426/10/4/265prostate canceroligometastatic diseasehistopathologyinflammationatrophygleason index |
| spellingShingle | Claudia Manini Alba González David Büchser Jorge García-Olaverri Arantza Urresola Ana Ezquerro Iratxe Fernández Roberto Llarena Iñaki Zabalza Rafael Pulido Arkaitz Carracedo Alfonso Gómez-Iturriaga José I. López Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer Journal of Personalized Medicine prostate cancer oligometastatic disease histopathology inflammation atrophy gleason index |
| title | Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer |
| title_full | Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer |
| title_fullStr | Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer |
| title_full_unstemmed | Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer |
| title_short | Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer |
| title_sort | oligometastatic prostate adenocarcinoma clinical pathologic study of a histologically under recognized prostate cancer |
| topic | prostate cancer oligometastatic disease histopathology inflammation atrophy gleason index |
| url | https://www.mdpi.com/2075-4426/10/4/265 |
| work_keys_str_mv | AT claudiamanini oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT albagonzalez oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT davidbuchser oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT jorgegarciaolaverri oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT arantzaurresola oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT anaezquerro oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT iratxefernandez oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT robertollarena oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT inakizabalza oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT rafaelpulido oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT arkaitzcarracedo oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT alfonsogomeziturriaga oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer AT joseilopez oligometastaticprostateadenocarcinomaclinicalpathologicstudyofahistologicallyunderrecognizedprostatecancer |